Reference : Pharma-clinics le medicament du mois. L'orlistat (xenical).
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/12576
Pharma-clinics le medicament du mois. L'orlistat (xenical).
French
[fr] Pharmacy-clinics medication of the month. Orlistate (xenical)
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Ernest, Philippe mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Letiexhe, Michel [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
1999
Revue Médicale de Liège
Hopital de Baviere
54
3
192-6
Yes (verified by ORBi)
0370-629X
Liège
Belgique
[en] Dietary Fats/metabolism ; Enzyme Inhibitors/administration & dosage/pharmacology/therapeutic use ; Humans ; Hypercholesterolemia/drug therapy ; Lactones/administration & dosage/pharmacology/therapeutic use ; Obesity/drug therapy ; Weight Loss
[en] Orlistat (tetrahydrolipstatin), launched by Roche under the trade name Xenical, is a selective inhibitor of pancreatic and gastro-intestinal lipases. It reduces the digestion of dietary fat and its resorption through digestive mucosa by around 30%. It is indicated, at a dose of 3 x 120 mg/day (one dose with each meal) and together with a moderately low-calorie and low-fat diet, for the treatment of obesity. It has been shown, in placebo-controlled two-year trials, to almost double the number of obese subjects who succeed in loosing at least 10% of initial body weight. Independently, it contributes to decrease serum cholesterol levels by 6-10%. Because of its mechanism of action, this drug can induce intestinal side-effects which tend to decrease with time and with the reduction of fat intake, thus improving diet compliance.
http://hdl.handle.net/2268/12576

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.